Evidence map›Paper›PMID 28819225›Full record

ArticleScientific reports2017

Cytochrome P450/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anopheles gambiae.

Carlos J Chaccour, Felix Hammann, Marta Alustiza, Sandra Castejon, Brian B Tarimo, Gloria Abizanda, Ángel Irigoyen Barrio, Helena Martí Soler, Rafael Moncada, José Ignacio Bilbao and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Veterinary endectocides for malaria control and elimination: prospects and challenges.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2021
    Article
  15. Study on individualized analgesia guided byAmerican journal of translational research · 2021
    Article
  16. Article
  17. The effect of ivermectinMalaria journal · 2019
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 5 countries.

Carlos J ChaccourInstituto de Salud Tropical, Universidad de Navarra, Pamplona, 31008, Spain. carlos.chaccour@isglobal.org.ORCID 0000-0001-9812-050X
Felix HammannDivision of Clinical Pharmacology and Toxicology, University Hospital Basel and University of Basel, Basel, 4056, Switzerland.
Marta AlustizaFaculty of Medicine, Universidad de Navarra, Pamplona, 31008, Spain.
Sandra CastejonDepartment of Microbiology, Clínica Universidad de Navarra, Pamplona, 31008, Spain.
Brian B TarimoIfakara Health Institute, Bagamoyo, Pwani, P.O. Box 74, United Republic of Tanzania.
Gloria AbizandaCentro de Investigación Médica Aplicada, Pamplona, 31008, Spain.
Ángel Irigoyen BarrioDrug Development Unit Universidad de Navarra (DDUNAV), Pamplona, 31008, Spain.
Helena Martí SolerISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, 08036, Spain.
Rafael MoncadaDepartment of Anaesthesia, Clínica Universidad de Navarra, Pamplona, 31008, Spain.
José Ignacio BilbaoDepartment of Radiology, Clínica Universidad de Navarra, Pamplona, 31008, Spain.
Azucena AldazDepartment of Pharmacy, Clínica Universidad de Navarra, Pamplona, 31008, Spain.
Marta MaiaIfakara Health Institute, Bagamoyo, Pwani, P.O. Box 74, United Republic of Tanzania.
José Luis Del PozoDepartment of Microbiology, Clínica Universidad de Navarra, Pamplona, 31008, Spain.
Clinica Universidad de Navarra · ESIfakara Health Institute · TZUniversidad de Navarra · ESBarcelona Institute for Global Health · ESInstituto de Salud Pública de Navarra · ESUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mass administration of endectocides, drugs that kill blood-feeding arthropods, has been proposed as a complementary strategy to reduce malaria transmission. Ivermectin is one of the leading candidates given its excellent safety profile. Here we provide proof that the effect of ivermectin can be boosted at two different levels by drugs inhibiting the cytochrome or ABC transporter in the mammal host and the target mosquitoes. Using a mini-pig model, we show that drug-mediated cytochrome P450/ABC transporter inhibition results in a 3-fold increase in the time ivermectin remains above mosquito-killing concentrations. In contrast, P450/ABC transporter induction with rifampicin markedly impaired ivermectin absorption. The same ketoconazole-mediated cytochrome/ABC transporter inhibition also occurs outside the mammal host and enhances the mortality of Anopheles gambiae. This was proven by using the samples from the mini-pig experiments to conduct an ex-vivo synergistic bioassay by membrane-feeding Anopheles mosquitoes. Inhibiting the same cytochrome/xenobiotic pump complex in two different organisms to simultaneously boost the pharmacokinetic and pharmacodynamic activity of a drug is a novel concept that could be applied to other systems. Although the lack of a dose-response effect in the synergistic bioassay warrants further exploration, our study may have broad implications for the control of parasitic and vector-borne diseases.

Indexed as

AnimalsAnophelesATP-Binding Cassette TransportersCytochrome P-450 CYP3A InhibitorsCytochrome P-450 Enzyme SystemDrug SynergismFeeding BehaviorFemaleHost-Parasite InteractionsHumansInsecticidesIvermectinKetoconazoleMaleMammalsMosquito ControlATP-Binding Cassette TransportersCytochrome P-450 CYP3A InhibitorsCytochrome P-450 Enzyme SystemInsecticidesIvermectinKetoconazole

Identifiers

PMID28819225
PMCPMC5561046
OpenAlexW2744546556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.